There haven't been many days where Bayer stages a 5+% rally.
- Perps are Unchanged in a market where XO is -7 tighter and 5yr OBL +35c
- Recent developments - marginal win in the PCB case in Washington insofar as the pay-out was only to 4 people, not all 15. $100m pay-out is manageable.
- The company ruled out any large M&A (did we think they would...?) at the JPM Health conference
- Xarelto lost exclusivity last April - but Nubeqa and Kerendia have been filling the gap in earnings.
- At the JPM conference, Bayer pointed to Pharma gains from 2027 onwards. BridgeBio is expected to produce $1bn+ sales.
- In women's health, elinzanetant should launch in July with $750m peak sales expected eventually.